Beacon Biomedical Inc. Appoints Industry Veteran To Lead Cancer Screening Technology Commercialization
Dr. Daniel Holterman is now Chief Science Officer and CLIA Lab Director at Beacon Biomedical
Dr. Holterman is a Ph.D. scientist with more than 25 years of advanced medical and scientific research focusing on oncology in such areas as biomarkers for disease, precision medicine and tumor immunology. He has served as Director of the Molecular Pathology Lab at Eastern Virginia Medical School, and his background includes Scientist at ImmuneRegen, Senior Scientist at Caris Life Sciences, and Director of the CLIA laboratory at VisionGate Biosignature Laboratories. Dr. Holterman has authored 13 peer-reviewed articles, made numerous presentations at scientific conferences worldwide, and has 8 issued patents on novel biomarkers for cancer diagnostics and therapeutics.
Holterman commented, "I am extremely excited to be joining the dynamic and innovative team at Beacon Biomedical in Phoenix, AZ. Beacon's management team has a history of successful biotechnology launches in the past. Our newest initiative to detect colon cancer, using a simple blood test with intellectual property that was developed at National Cancer Institute, truly has the potential to dramatically reduce deaths from the number two cancer killer of Americans. We expect to launch our diagnostic assay in the fourth quarter of this year."
Dr. Holterman received his Ph.D. from Old Dominion University and Eastern Virginia Medical School in Biomedical Sciences/Tumor Immunology and his B.S. degree in Immunology/Serology from Pennsylvania State University.
Don Weber, Beacon Biomedical's CEO, added, "The key to an organization's success is the talent of its people and their shared commitment to the company's vision and mission. Dr. Holterman brings such a talent and commitment to Beacon. His experience and expertise in tumor immunology R&D and the cancer diagnostic space is second to none, and I am thrilled Dan is on board leading Beacon's scientific staff and efforts as Chief Science Officer and CLIA Lab Director."
About Beacon Biomedical, Inc.
Beacon Biomedical, Inc. is a privately held assay development and medical device company focused on developing and commercializing easy, accurate and affordable colorectal, breast and lung cancer screening solutions. Beacon has secured the exclusive worldwide rights from the National Institutes of Health for the development and commercialization of an oncoprotein called Cripto-1 (i.e., teratocarcinoma derived growth factor-1) that has demonstrated the ability in multiple independent studies to differentiate colorectal cancer (CRC) from healthy controls at 95% accuracy in blood-based samples. Additional information about Beacon Biomedical is available at https://www.beaconbiomedical.com.